really have entered this new era of direct acting antivirals, and as of
this fall, we’ve finally laid to rest Interferon in the grave that
we’ve all been wanting to put it in, for more than 2 decades,” opened
Jacqueline G. O’Leary, MD, MPH, AGAF during her presentation at the 2015
AGA Clinical Congress of Gastroenterology & Hepatology.
According to O’Leary, sofosbuvir certainly changed everything – a truly
pangenotypic polymerase inhibitor (NSSB) prescribed as 400 mg daily,
never modified with no significant food effect reported. It had recently
been co-formulated with ledipasvir, the first in class NSSA inhibitor,
once daily dose, and also with no existing food effect.
Switching gears, O’Leary discussed the other FDA approved all oral regiment of paritapevir with ombitasvir and dasabuvir, for their genotype 1 patients. “This is a trick from HIV that allows lower dosing in medication, a dramatic increase in half-life, which adds an additional protection. This is binding against the thumb blood site, which definitely gets two thumbs up, because it allows you to give the finger to hepatitis C.”
- See more at: http://www.hcplive.com/conferences/aga-2015/Hepatitis-C-What-Therapy-this-Week#sthash.XnTiU8TC.dpuf
Labels: AGA, treatment updates, treatmnent developments